Entrada Therapeutics
TRDA · NASDAQ
$4.99+$0.17 (+3.53%)TodayMarket closed ·
Prev close $4.82
EPS: actual vs estimate
Beat the estimate in 6 of the last 8 quarters, by 40.1% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$1.07 | -$1.01 | +5.7% |
| Q1 FY26 | -$1.06 | -$0.95 | +10.2% |
| Q4 FY25 | -$1.17 | -$0.94 | +19.9% |
| Q3 FY25 | -$0.9588 | -$1.06 | −10.6% |
| Q2 FY25 | -$0.8645 | -$1.04 | −20.3% |
| Q1 FY25 | -$0.8048 | -$0.42 | +47.8% |
| Q4 FY24 | -$0.6832 | $0.03 | +104.4% |
| Q3 FY24 | -$0.7426 | -$0.35 | +52.9% |
Earnings calls
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- TRDA - Earnings call Q1 2026
- 44th Annual J.P. Morgan Healthcare Conference
- Special Call - Entrada Therapeutics, Inc.
- Goldman Sachs 46th Annual Global Healthcare Conference 2025
- 43rd Annual J.P. Morgan Healthcare Conference 2025
- Goldman Sachs 45th Annual Global Healthcare Conference
- Goldman Sachs 44th Annual Global Healthcare Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.